Related Experiment Video
Updated: Jan 31, 2026
Phage-Mediated Genetic Manipulation of the Lyme Disease Spirochete Borrelia burgdorferi
Published on: September 28, 2022
Lyme Neuroborreliosis
Sebastian Rauer1, Stefan Kastenbauer, Volker Fingerle
1Department of Neurology and Neurophysiology, Medical Center-University of Freiburg; Neurologische Praxis, München; National Reference Centre for Borrelia, Bavarian Health and Food Safety Authority, Oberschleissheim; Institute for Laboratory Medicine, Microbiology and Hospital Hygiene, Krankenhaus Nordwest, Frankfurt/Main; Klinikum Bremen Mitte, Prof.-Hess-Kinderklinik and Clinic for Pediatric Intensive Care, Bremen; Evidence in Medicine / Cochrane Germany, Medical Center, Faculty of Medicine, University of Freiburg; *All of the editors, authors, and processors of the German S3 guideline on Lyme neuroborreliosis are listed in the eBox.
Insights
Early treatment of Lyme neuroborreliosis offers a favorable prognosis. Oral doxycycline is as effective as intravenous antibiotics for early stages, with shorter treatment durations proving sufficient and avoiding risks of prolonged therapy.
Area of Science:
- Infectious Diseases
- Neurology
- Evidence-Based Medicine
Background:
- The German S3 guideline provides evidence-based recommendations for diagnosing and treating Lyme neuroborreliosis.
- Lyme neuroborreliosis is a significant neurological manifestation of Borrelia infection.
Purpose of the Study:
- To update and disseminate scientifically grounded information on Lyme neuroborreliosis diagnosis and treatment.
- To guide physicians in managing Lyme neuroborreliosis effectively.
Main Methods:
- Systematic literature search conducted from March 2014 for 12 months.
- Searched Medline, Embase, and Cochrane Register using terms including "Lyme disease," "neuroborreliosis," and neurological manifestations.
- Publications were critically assessed by the German Cochrane Center.
Main Results:
- Oral doxycycline demonstrates equivalent efficacy to intravenous beta-lactam antibiotics for early Lyme neuroborreliosis (RR: 0.98, 95% CI: [0.68; 1.42]).
- A 14-day treatment course is sufficient for early Lyme neuroborreliosis.
- 14-21 days of treatment are generally adequate for late (chronic) Lyme neuroborreliosis.
Conclusions:
- Early diagnosis and treatment of Lyme neuroborreliosis lead to a favorable prognosis.
- Extended antibiotic therapy for chronic Lyme neuroborreliosis with nonspecific symptoms provides no added benefit.
- Prolonged antibiotic use increases the risk of adverse effects.
Background:
The new German S3 guideline on Lyme neuroborreliosis is intended to provide physicians with scientifically based information and recommendations on the diagnosis and treatment of this disease.
Methods:
The scientific literature was systematically searched and the retrieved publications were assessed at the German Cochrane Center (Deutsches Cochrane Zentrum) in Freiburg in the 12 months beginning in March 2014. In addition to the main search terms "Lyme disease," "neuroborreliosis," "Borrelia," and "Bannwarth," 28 further terms relating to neurological manifestations of the disease were used for the search in the Medline and Embase databases and in the Cochrane Central Register of Controlled Trials.
Results:
In the treatment of early Lyme neuroborreliosis, orally administered doxycycline is well tolerated, and its efficacy is equivalent to that of intravenously administered beta-lactam antibiotics (penicillin G, ceftriaxone, and cefotaxime) (relative risk [RR]: 0.98, 95% confidence interval [CI]: [0.68; 1.42], P = 0.93). 14 days of treatment suffice for early Lyme neuroborreliosis, and 14-21 days of treatment usually suffice for late (chronic) Lyme neuroborreliosis.
Conclusion:
Lyme neuroborreliosis has a favorable prognosis if treated early. The long-term administration of antibiotics over many weeks or even months for putative chronic Lyme neuroborreliosis with nonspecific symptoms yields no additional benefit and carries the risk of serious adverse effects.
